As of January 1st, 2022, IP Journal of Urology, Nephrology and Hepatology Science will be ceased publication with IP Innovative Publication. IP Innovative Publication will not publish new content starting from 2022, but will continue to host all published content from 2018-2021, which can be accessed via www.ipinnovative.com/journals/IJUNHS



Print ISSN:-XXXX

Online ISSN:-XXXX

Issue

Year 2021

Volume: 4 , Issue: 4

IP Journal of Urology, Nephrology and Hepatology Science

Role of target therapy in gastric cancer


Full Text PDF


Article Type : Review Article

Author Details: J. Pandiaraja*

Volume : 4

Issue : 3

Online ISSN : XXXX

Print ISSN : XXXX

Article First Page : 67

Article End Page : 74

Abstract

Gastric cancer is one of the most common gastrointestinal malignancies associated with higher mortality and a high recurrence rate. Early detected gastric cancer can be managed endoscopically or laparoscopically. The management of locally advanced and metastatic gastric cancer is particularly difficult. Conventional chemotherapy is not useful in all patients with advanced disease. In those patients, the only hope of treatment at present is target therapy. Apart from metastatic disease, target therapy is also useful in a patient with chemoresistance gastric cancer and gastric cancer who failed to respond to conventional chemotherapy

Keywords: Gastric cancer, target therapy, HER2, VEGFR, c-MET, mTOR, Claudin, Immunotherapy

Doi No:-10.18231



Sitemap | Advertise | Feedback
©2020 Ip Journal Of Urology, Nephrology And Hepatology Science | Published by IP Innovative Publication Pvt. Ltd. (www.ipinnovative.com)
Online since 26th December, 2020
Ip Journal Of Urology, Nephrology And Hepatology Science is licensed under a Creative Commons Attribution - Attribution 4.0 International (CC BY 4.0).
Editorial and Ethics Policies
Print ISSN: XXXX Online ISSN: XXXX